about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Re­jig­ging Mer­ck KGaA part­ner­ship, Eliot Forster gains full con­trol of the al­pha in F-star's con­stel­la­tion

7 years ago
R&D

What's tak­ing the FTC so long? Roche won't say, but in­sists it will bag Spark on time — de­spite third de­lay

7 years ago
Deals

Min­er­va claims 'pos­i­tive' PhII da­ta on de­pres­sion drug while skep­tics push stock down

7 years ago
R&D

‘Too big to care’: Sweep­ing law­suit ac­cus­es Te­va of col­lud­ing with oth­er gener­ic mak­ers to keep prices high

7 years ago
Pharma

Genky­otex picks out sil­ver lin­ings from failed PhII, braces for piv­otal study in pri­ma­ry bil­iary cholan­gi­tis

7 years ago
R&D

Mi­cro­cap biotech Vista­Gen turned to pen­ny­s­tock af­ter PhII re­sults show its de­pres­sion drug does­n't work so­lo

7 years ago
R&D

Tes­sa show­cas­es pre­clin­i­cal promise of 'all-in-one' add-on to its can­cer cell ther­a­py, in march to the clin­ic

7 years ago
Discovery
Cell/Gene Tx

As­traZeneca bets cau­tious­ly on on­colyt­ic virus dis­cov­ery pro­gram, out­lin­ing $13M deal with Trans­gene

7 years ago
R&D
Discovery

Ab­b­Vie nabs pe­di­atric OK for hep C drug Mavyret; Glen­mark launch­es cheap­er SGLT2 in­hibitor in In­dia

7 years ago
News Briefing

Man­u­fac­tur­ing con­cerns spike Nabri­va’s plans to launch its first an­tibi­ot­ic — for now

7 years ago
R&D

Roche spins out Nim­ble Ther­a­peu­tics to cap­i­tal­ize on pep­tide drug dis­cov­ery, with $10M sup­port from Tele­graph Hill ...

7 years ago
Startups

Top 5 Chi­nese play­ers: What does Ever­est's land­mark deal with Im­munomedics say about the flur­ry of in-li­cens­ing to ...

7 years ago
China

Co­di­ak Bio­sciences out­lines a new fo­cus for its ex­o­some plat­form in $86M IPO fil­ing

7 years ago
Financing

A biotech fledg­ling cross-bred in France and Switzer­land launch­es to take on liv­er prob­lems of glob­al di­men­sions

7 years ago
Financing
Startups

FDA tags Bay­er's prostate can­cer drug for pri­or­i­ty re­view as drug­mak­er gears up against ri­vals

7 years ago
R&D

Eye­ing RNAi po­ten­tial in can­cer and fi­bro­sis, trans-Pa­cif­ic biotech Sir­naomics lines up $47M Se­ries C

7 years ago
Financing

Peer Re­view: Don Hay­den com­mits to CEO role at Wind­MIL; X4 nabs new CMO Lynne Kel­ley from His­to­gen­ics ex­ile

7 years ago
Peer Review

Keytru­da PhI­II fail­ure in gas­tric can­cer blights Mer­ck­'s quest for front­line dom­i­nance

7 years ago
R&D
Pharma

Roche de­lays $4.3B Spark buy­out — again — as FTC re­view drags on

7 years ago
Deals

Nine list­ings and $3.8B lat­er, HKEX cel­e­brates one-year biotech an­niver­sary with $194M CRO IPO

7 years ago
Financing
China

Gilead­'s selon­sert­ib fails PhI­II in less sick NASH pa­tients — to no one's sur­prise

7 years ago
R&D

Tout­ing su­pe­ri­or nasal de­liv­ery, Sat­suma bags $62M for new for­mu­la­tion of old mi­graine drug

7 years ago
Financing

MD An­der­son tries to as­sure re­searchers in town hall meet­ing that Asian ‘eth­nic­i­ty’ is not the dri­ving force ...

7 years ago
China

Drug dis­trib­u­tor, for­mer ex­ecs charged for fu­el­ing opi­oid cri­sis as le­gal cam­paign widens its scope

7 years ago
Pharma
First page Previous page 99100101102103104105 Next page Last page
A service from the Financial Times